Alembic Pharmaceuticals has received USFDA approval for Solifenacin Succinate tablets which are used for treatment of over-active bladder. The product Solifenacin Succinate is a generic equivalent of Vesicare tablets of Astellas Pharma US Inc.
According to market estimates, Solifenacin Succinate tablets 5 mg and 10 mg had an estimated market size of USD 967 million for 12 months, ending December 2018.
Company Profile : Alembic Pharmaceuticals Ltd
Leave a Reply